285 related articles for article (PubMed ID: 17194390)
1. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
2. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
3. [Lipid disorders in patients with HIV-induced diseases].
Chanu B; Valensi P
Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
[TBL] [Abstract][Full Text] [Related]
4. Class of antiretroviral drugs and the risk of myocardial infarction.
; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular risk factors associated with antiretroviral therapy].
Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
[TBL] [Abstract][Full Text] [Related]
8. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
9. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
12. The nurse practitioner's role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy.
Willard S
J Assoc Nurses AIDS Care; 2006; 17(1):7-17. PubMed ID: 16686080
[TBL] [Abstract][Full Text] [Related]
13. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
15. The role of statins in the setting of HIV infection.
Eckard AR; McComsey GA
Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
[TBL] [Abstract][Full Text] [Related]
16. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.
Rodríguez-Gallego E; Gómez J; Domingo P; Ferrando-Martínez S; Peraire J; Viladés C; Veloso S; López-Dupla M; Beltrán-Debón R; Alba V; Vargas M; Castellano AJ; Leal M; Pacheco YM; Ruiz-Mateos E; Gutiérrez F; Vidal F; Rull A;
Atherosclerosis; 2018 Jun; 273():28-36. PubMed ID: 29677628
[TBL] [Abstract][Full Text] [Related]
17. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
The RESPOND Study Group
AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
[TBL] [Abstract][Full Text] [Related]
18. Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT
Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia in HIV-infected individuals.
Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
[TBL] [Abstract][Full Text] [Related]
20. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
Ahmed MH; Al-Atta A; Hamad MA
Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
